Stockscreener 앱 받기
2.87
5.28%
-0.16
시장 영업 전:
2.88
0.010
+0.35%
전일 마감가:
$3.03
열려 있는:
$3.02
하루 거래량:
7.62M
Relative Volume:
1.71
시가총액:
$236.98M
수익:
-
순이익/손실:
$-314.85M
주가수익비율:
-0.8011
EPS:
-3.5825
순현금흐름:
$-283.27M
1주 성능:
+11.67%
1개월 성능:
-65.87%
6개월 성능:
-66.55%
1년 성능:
-71.33%
1일 변동 폭
$2.52
$3.09
1주일 범위
$2.335
$3.14
52주 변동 폭
$1.50
$13.24
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
2.87 | 236.98M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | 다운그레이드 | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2026-04-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-04-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-04-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-10-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-09-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN
FDA Commissioner Makary defends agency’s decision on Replimune’s drug, CNBC reports - hi99.com
FDA head Makary defends drug application rejections amid criticism - Seeking Alpha
REPL Stock Plunges As FDA Rejects Key Melanoma Therapy - StocksToTrade
What's Going On With Replimune Stock On Tuesday? - Benzinga
REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: ‘I Don’t Work For Replimune…’ - Stocktwits
REPL Stock Plunges As FDA Rejection Triggers Legal And Wall Street Backlash - timothysykes.com
FDA Commissioner Makary defends agency's decision on Replimune's drug, CNBC reports - Reuters
FDA Commissioner Makary defends agency's decision on Replimune's drug - marketscreener.com
Fda's Makary on Replimune's Drug Says If the Clinical Trials Show That It Works, It's Going to Get ApprovedCnbc - marketscreener.com
Fda's Makary on Replimune Says Three Indepndent Teams Arrived at the Same ConclusionsCnbc - marketscreener.com
Fda's Makary Defends Agency's Decision On Replimune's Cancer Drug -Cnbc - marketscreener.com
Replimune plunges after FDA rejects skin cancer drug again - MSN
REPL stock rallies in anticipation of FDA decision on skin cancer drug - MSN
FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients - The Cancer Letter
Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 12.8% - MarketBeat
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - PR Newswire
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, In - The National Law Review
Replimune Group (REPL) price target decreased by 59.94% to 5.04 - MSN
Street sours on Replimune as stock hits all-time low on melanoma drug rejection - MSN
MSN Money - MSN
MSN - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Shareholders to Connect - ACCESS Newswire
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - FinancialContent
Opinion | Replimune’s Fate Is Worse Than a Tragedy - WSJ
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out - ACCESS Newswire
Replimune under pressure as FDA rejects lead asset again - MSN
2026-04-27 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out | NDAQ:REPL | Press Release - Stockhouse
Replimune brings 3-year melanoma survival data to ASCO oral session - Stock Titan
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
200+ Mass. biotech employees were laid off last week. That may only be the beginning - MSN
Wedbush Upgrades Replimune Group (REPL) - MSN
Replimune plans layoffs as FDA rejects cancer drug - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
REPL Stock Crashes As FDA Rejects RP1 Melanoma Bid Again - StocksToTrade
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid - StocksToTrade
REPL Stock Collapses As FDA Rejection Triggers Downgrades - StocksToTrade
JP Morgan Downgrades Replimune Group (REPL) - MSN
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):